Floatz logo

Ravuconazole

Gestational Trophoblastic Tumor

National Institutes of Health Clinical Center (CC)Small moleculePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Gestational Trophoblastic Tumor cohort.

Asset / SponsorPhaseRating
Amifostine
Gynecologic Oncology Group
Phase 3B
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2B
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Fred Hutchinson Cancer Center
Phase 2B
MOXIFLOXACIN
OHSU Knight Cancer Institute
Phase 3B
Sargramostim
Cancer Treatment Centers of America
Phase 2B

View all 25 →

Same molecule, other indications

Ravuconazole is also rated in:

myelodysplastic/myeloproliferative neoplasmDormant
CCC
Indicative ·
52 / 100
View asset →
infectious diseaseDormant
CCC
Indicative ·
52 / 100
View asset →
testicular germ cell tumorDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →